{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:23:14Z","timestamp":1783117394123,"version":"3.54.6"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Ewing sarcoma (ES) is the second most common malignant bone and soft tissue tumor in children, adolescents, and young adults. Current consensus guidelines, consistent with Children\u2019s Oncology Group practice, support the universal use of full-body fluorodeoxyglucose positron emission tomography (FDG-PET) and recommend reserving bone marrow aspiration and biopsy for cases in which FDG-PET raises concern for marrow involvement, leaving final decisions to the treating physician. Although bone marrow metastasis is defined by morphologic evidence on biopsy rather than imaging alone, the extent to which these recommendations have influenced real-world practice is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cross-sectional electronic survey of pediatric hematology-oncology and transplant attending physicians, advanced practice providers, and fellows was conducted to gather data on current practices regarding FDG-PET use and the decision to include bone marrow evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 392 providers completed this survey. Nearly all general oncologists (n=172) and solid tumor specialists (n=156) reported obtaining an FDG-PET for every patient presenting with ES, compared with all other hematology\/oncology subspecialty providers (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.002). Providers who always obtain FDG-PET for newly diagnosed ES patients had a lower median year in practice (9 [3 to 17]) than those who do not (19 [8 to 21]) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.018). However, more than half of providers reported obtaining a BM biopsy on every patient, independent of FDG-PET results. Based on a guideline-informed system, solid tumor oncologists demonstrated somewhat greater alignment with practice-based approaches compared with general oncologists (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.013).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>This study highlights the variation in the diagnostic evaluation of ES. Increased education and incorporation of practice-based guidelines into upfront clinical trials may help reduce practice variability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003218","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:00:30Z","timestamp":1781190030000},"page":"e205-e208","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Current Practices and Variations in the Use of FDG-PET and Bone Marrow Biopsy in Ewing Sarcoma Diagnosis: A Survey of Provider Recommendations"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-6457","authenticated-orcid":false,"given":"Rachel","family":"Offenbacher","sequence":"first","affiliation":[{"name":"Pediatrics"},{"name":"Division of Pediatric Hemato-Oncology, The Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Epstein","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson B.","family":"Collier","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Nemours Children\u2019s Health, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lin","sequence":"additional","affiliation":[{"name":"Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Dean","family":"Hosgood","sequence":"additional","affiliation":[{"name":"Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Moerdler","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"R1-20260703","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/ijc.33674","article-title":"Comparative international incidence of Ewing sarcoma 1988 to 2012","volume":"149","author":"Spector","year":"2021","journal-title":"Int J Cancer"},{"issue":"suppl 4","key":"R3-20260703","doi-asserted-by":"crossref","first-page":"e30000","DOI":"10.1002\/pbc.30000","article-title":"Imaging of pediatric bone tumors: a COG Diagnostic Imaging Committee\/SPR Oncology Committee white paper","volume":"70 suppl 4","author":"Cederberg","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"R4-20260703","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1002\/cncr.34942","article-title":"Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board","volume":"129","author":"Gupta","year":"2023","journal-title":"Cancer"},{"key":"R6-20260703","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.24406","article-title":"An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and BM aspiration\/biopsy as staging investigations in Ewing sarcoma","volume":"60","author":"Newman","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20260703","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/pbc.25212","article-title":"Utility of BM aspiration and biopsy in initial staging of Ewing sarcoma","volume":"62","author":"Kopp","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R8-20260703","doi-asserted-by":"crossref","first-page":"e27653","DOI":"10.1002\/pbc.27653","article-title":"BM biopsy in the initial staging of Ewing sarcoma: experience from a single institution","volume":"66","author":"Cesari","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20260703","doi-asserted-by":"crossref","first-page":"e28807","DOI":"10.1002\/pbc.28807","article-title":"Role of BM biopsy for staging new patients with Ewing sarcoma: a systematic review","volume":"68","author":"Campbell","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20260703","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.3390\/cancers13133261","article-title":"Is it time to call time on BM biopsy for staging Ewing sarcoma (ES)?","volume":"13","author":"Ingley","year":"2021","journal-title":"Cancers"},{"key":"R11-20260703","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2022.11.002","article-title":"Staging of newly diagnosed Ewing sarcoma: results of BM aspiration and biopsy versus (18)FDG-PET\/CT imaging for BM involvement","volume":"179","author":"Guinot","year":"2023","journal-title":"Eur J Cancer"},{"key":"R12-20260703","doi-asserted-by":"crossref","first-page":"e29415","DOI":"10.1002\/pbc.29415","article-title":"18F-FDG PET and PET\/CT as a diagnostic method for Ewing sarcoma: a systematic review and meta-analysis","volume":"69","author":"Seth","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20260703","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1002\/cncr.34942","article-title":"Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board","volume":"129","author":"Gupta","year":"2023","journal-title":"Cancer"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:00:27Z","timestamp":1783116027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003218","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"2026-01-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}